{"nctId":"NCT00550953","briefTitle":"Filtered Trial for Telmisartan 40mg Non-responder","startDateStruct":{"date":"2007-10"},"conditions":["Hypertension"],"count":314,"armGroups":[],"interventions":[{"name":"telmisartan+amlodipine","otherNames":[]},{"name":"telmisartan","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Essential hypertensive patients who satisfying non-responder criteria\n2. Male or Female\n3. Age 20 years or older\n4. Outpatient\n\nExclusion Criteria:\n\n1. Taking four or more anti-hypertensive medications\n2. Secondary hypertension\n3. Mean seated diastolic blood pressure (DBP) \\> 114 mmHg and/or mean seated systolic blood pressure (SBP) \\> 200 mmHg at Visit 1, 2, 3, or 4, or mean seated DBP \\< 90 mmHg at Visit 3.\n4. Sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias\n5. Congestive heart failure patients with the New York Heart Association (NYHA) functional class III-IV\n6. History of myocardial infarction or cardiac surgery within last 6 months\n7. History of coronary artery bypass graft or percutaneous coronary intervention (PCI) within last 3 months\n8. History of unstable angina within last 3 months\n9. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve\n10. History of stroke or transient ischemic attack within last 6 months\n11. History of sudden exacerbation of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors, or patients with post-renal transplant or post-nephrectomy\n12. Experienced characteristic symptoms of angioedema during treatment with ARBs or ACE inhibitors\n13. Known hypersensitivity to any component of the investigational drug , or a known hypersensitivity to dihydropyridine -derived drugs\n14. Hepatic and/or renal dysfunction\n15. Diagnosed biliary atresia or cholestasis\n16. Hyperkalemia\n17. Dehydration\n18. Sodium deficiency\n19. Chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs (NSAIDs)\n20. Patients who cannot change to the restricted administration and dosage during study period\n21. Pre-menopausal women who meet any one of the following 1 - 3:\n\n    * Pregnant or possibly pregnant (1)\n    * Nursing (2)\n    * Desire to become pregnant during study period (3)\n22. Drug or alcohol dependency\n23. Complication of malignant tumour or a disease requiring immunosuppressants\n24. Compliance of \\< 80% or \\> 120% during the run-in period\n25. Receiving any investigational therapy within 3 months\n26. Judged to be inappropriate by the investigator or the sub-investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks","description":"The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.49","spread":"0.63"},{"groupId":"OG001","value":"5.47","spread":"0.62"}]}]}]},{"type":"SECONDARY","title":"Decrease in Seated Systolic Blood Pressure From Baseline to 8 Weeks","description":"The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.86","spread":"0.86"},{"groupId":"OG001","value":"6.51","spread":"0.84"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)","description":"Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.4","spread":null},{"groupId":"OG001","value":"46.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)","description":"Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":null},{"groupId":"OG001","value":"37.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)","description":"Adequate response defined that seated trough diastolic blood pressure was \\<90 mmHg or decreased from reference baseline by \\>=10 mmHg at 8 weeks","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks (0 Percent at Baseline)","description":"Adequate response defined that seated trough systolic blood pressure was \\<140 mmHg or decreased from reference baseline by \\>=20 mmHg at 8 weeks (0 percent at baseline)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null},{"groupId":"OG001","value":"58.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)","description":"Optimal, normal, high normal blood pressure were defined as follows:\n\n* Optimal: Systolic blood pressure (SBP) \\< 120 mmHg and diastolic blood pressure (DBP) \\< 80 mmHg\n* Normal: SBP \\>= 120 mmHg or DBP \\>= 80 mmHg and SBP \\< 130 mmHg and DBP \\< 85 mmHg\n* High normal: SBP \\>= 130 mmHg or DBP \\>= 85 mmHg and SBP \\< 140 mmHg and DBP \\< 90 mmHg","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":null},{"groupId":"OG001","value":"3.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.7","spread":null},{"groupId":"OG001","value":"17.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":null},{"groupId":"OG001","value":"17.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG","description":"Clinical relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":156},"commonTop":["Nasopharyngitis"]}}}